This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 22, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended
March 31, 2014, at
8:00 a.m. U.S. Eastern Daylight Time on
Thursday, May 1, 2014. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the first quarter and business outlook. The call may be accessed by dialing 1-877-407-0789 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the U.S., please dial +1-201-689-8562.
A live webcast of the call will also be available in the Investor section at the Company's website (
http://ir.heartware.com/). A replay of the conference call will be available through the above weblink immediately following completion of the call.
A copy of the news release announcing results and related information will be available on the Company's website,
About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare
® Ventricular Assist System features the HVAD
® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in
the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 37 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at